In summary, acetylation on lysines 185 and 201 of AKR1C1 dictates its pro-metastatic potential, and the reverting of acetylation by Sirtuin 2 provides potential therapeutic targets for treatment against metastatic NSCLC patients with high AKR1C1 expression. The gene discussed is SIRT2; the disease is non-small cell lung carcinoma.